AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9

Adeno-associated viral (AAV) vectors are a leading candidate for the delivery of CRISPR-Cas9 for therapeutic genome editing in vivo. However, AAV-based delivery involves persistent expression of the Cas9 nuclease, a bacterial protein. Recent studies indicate a high prevalence of neutralizing antibod...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Mol Ther
Huvudupphovsmän: Li, Ang, Tanner, Mark R., Lee, Ciaran M., Hurley, Ayrea E., De Giorgi, Marco, Jarrett, Kelsey E., Davis, Timothy H., Doerfler, Alexandria M., Bao, Gang, Beeton, Christine, Lagor, William R.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Gene & Cell Therapy 2020
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7264438/
https://ncbi.nlm.nih.gov/pubmed/32348718
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2020.04.017
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk